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ScienceDirectIn a prototypical response to an acute viral infection it would be
expected that the adaptive immune response would eliminate
all virally infected cells within a few weeks of infection. However
many (non-retrovirus) RNA viruses can establish ‘within host’
persistent infections that occasionally lead to chronic or
reactivated disease. Despite the importance of ‘within host’
persistent RNA virus infections, much has still to be learnt about
the molecular mechanisms by which RNA viruses establish
persistent infections, why innate and adaptive immune
responses fail to rapidly clear these infections, and the
epidemiological and potential disease consequences of such
infections.
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Introduction
Infections with most non-retroviral RNA viruses cause
characteristic signs and symptoms of an acute disease.
During the acute phase of infection, the virus replicates
rapidly and is shed into the environment with spread to
new susceptible individuals. Recovery is typically associ-
ated with virus clearance and establishment of varying
lengths of immunity to re-infection. For such viruses to be
maintained within a population there needs to be a
continuous supply of susceptible individuals to sustain
the transmission cycle. For viruses, other than endoge-
nous retroviruses and viruses transmitted vertically, if the
host population size and/or density is small, as was likely
the case during most of human evolution and is currently$ This opinion piece takes its title from a conference with the same
name that was held in St Andrews, Scotland on 24th–26th August 2016
www.sciencedirect.com the situation for many animal populations, the number of
susceptible individuals may not remain high enough for
the virus to maintain itself within a host population.
Conversely, if the population density is very high, for
example in bat colonies, virus spread may be extremely
rapid thereby also leading to a decrease in the numbers of
susceptibles (through the induction of long-lasting pro-
tective immunity [1] and/or through high mortality rates)
to levels below that required for continued virus trans-
mission [2]
Because viruses are obligate intracellular parasites that
must be maintained in a population, RNA viruses have
evolved a number of strategies to counteract the potential
problem of ‘running out’ of susceptible individuals, such
as: (i) a high mutation rate that results in ongoing immune
selection of antigenic variants (e.g. influenza virus), (ii)
infection of mucosal surfaces, where it is difficult to
induce long lasting protective immunity, resulting in
repeated infections with the same virus (e.g. respiratory
syncytial virus) or (iii) infection of multiple species,
thereby increasing the numbers of susceptible individu-
als. As an additional strategy some viruses, such as hepa-
titis C virus (HCV) and Borna disease virus (BDV), have
evolved specific mechanisms that lead to the establish-
ment of persistent infections in at least some individuals
who can then act as reservoirs for the virus within a host
population.
In a prototypical response to an acute viral infection it is
expected that a virus will be cleared by innate and
adaptive immune responses within a few weeks of infec-
tion. Therefore, any infection that persists longer than
this may be considered persistent, even if it does not lead
to life-long infection with the production of infectious
virus. Indeed, for foot and mouth disease virus (FMDV),
cattle are considered persistently infected if infectious
virus can be detected for more than 28 days after infection
[3,4]. Not all persistent infections may represent a selec-
tive advantage for a virus. Thus viruses, or viruses with
defective genomes, may persist and slowly spread from
cell to cell without the production of infectious virus.
Such infections may nevertheless have important con-
sequences for the host in that they may lead to chronic or
even fatal disease outcomes, for example persistent mea-
sles virus (MeV) infections of the brain can lead to
subacute sclerosing panencephalitis (SSPE) [5,6], or they
may induce life-long immunity thereby preventing reoc-
currence of the acute infection, as has been suggested for
MeV [7]. It is this broad definition of persistence that weCurrent Opinion in Virology 2017, 23:35–42
36 Viral pathogenesiswill use in this opinion piece as we consider some of the
outstanding issues regarding ‘Within host RNA virus
persistence’.
Epidemiological consequences of persistent infections
The ability of some RNA viruses, for example HCV and
BDV, to establish persistent infections in a significant
proportion of infected hosts is critical for them to be
maintained within their host communities. However,
the importance of persistent infections for the epidemi-
ology of other viruses has yet to be established (Table 1),
particularly those that cause acute infections with obvious
clinical outcomes. However, the example of FMDV is
instructive. Although FMDV is best known for causing
devastating outbreaks of acute disease in domesticated
ungulates (e.g. cows and sheep), it can also establish
persistent infections in some animals (persistently
infected sheep and goats can shed virus for up to 9 months,
cattle for up to 2.5 years and buffalo for >5 years) which
can act as a source of FMDV in future outbreaks [3,4].Table 1
Examples of viruses that can establish persistent infections, including
Arenaviridae,
Mammarenaviruses, for example lymphocytic choriomeningitis virus [81
Arteriviruses, for example equine arteritis virus, simian haemorrhagic fever
Bornaviridae, for example Borna disease virus [83]
Bunyaviridae
Hantaviruses [37,38,84]
Caliciviridae
Noroviruses, for example Norwalk virus [85]
Coronaviridae, for example mouse hepatitis virus [86]
Endornaviridae and Partiviridae; [87]
Filoviridae,
Ebolaviruses, for example Ebola virus [20,68]
Marburg viruses, for example Marburg virus [88]
Flaviviridae
Hepacivuses, for example hepatitis C virus [89]
Pegivirus, for example GB viruses [90]
Flavivirus, for example West Nile virus [91], Zika [15,67], Japanese ence
Pestiviruses, for example Bovine viral diarrhoea virus [70,94,95]
Nodaviridae, for example flock house virus of insects [35,96]
Orthomyxoviridae, for example influenza viruses [97,98]
Paramyxoviridae [11]
Morbilliviruses, for example measles virus [99], canine distemper virus [
Respiroviruses, for example parainfluenza virus type 3 [103]
Rubulaviruses, for example parainfluenza virus type 5 [104], porcine rub
Picornaviridae
Aphthoviruses, for example foot-and-mouth disease virus [4]
Cardioviruses, for example Theilers murine encephalomyelitis virus [106
Enteroviruses, for example poliovirus [62], coxsackievirus [31], rhinoviru
Pneumoviridae, for example respiratory syncytial virus [107–109]
Reoviridae
Orbivirus, for example bluetongue virus [21–23]
Phytoreovirus, for example rice gall dwarf virus [34]
Rhabdoviridae
Lyssaviruses, for example rabies virus [110,111]
Togaviridae
Alphaviruses, for example Chikungunya virus [112]
Rubiviruses, for example rubella virus [113]
See also arboviruses [13]
Current Opinion in Virology 2017, 23:35–42 Similarly, swine vesicular disease virus may be able
establish persistent infections in pigs (>100 days) that
may act as carriers of swine vesicular disease [8]. There is
also evidence that acute respiratory viruses, such as
rhinoviruses [9,10] and respiratory paramyxoviruses
[11], establish persistent infections in some individuals
with production of infectious virus for many weeks or
months, although such infections are often, but not
always, associated with immune dysfunction (see below)
and/or age. Also, whilst many arboviruses are able to
establish inapparent life-long persistence in their arthro-
pod vector [12], they often cause significant acute disease
in their vertebrate hosts, although their ability to establish
persistence in vertebrates may have been under-esti-
mated [13].
Even such obviously acute virus infections such as Zika
virus and Ebola virus in humans can persist in very small
numbers of individuals over a period of months, and
perhaps years, and such persistently infected individuals in immunocompromised hosts, and some associated references
]
 virus [82]
phalitis virus [92], tick borne encephalitis virus [93]
100], feline morbillivirus [101,102]
ulavirus [105]
]
ses [9,10], swine vesicular disease virus [8]
www.sciencedirect.com
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Table 2
Examples of human diseases associated, sometimes controver-
sially, with persistent RNA virus infections and some associated
references
Autoimmune diseases: various viruses [114,115]
Chronic fatigue syndrome: enteroviruses [116]
Exacerbation of chronic obstructive pulmonary disease: Respiratory
syncytial virus [108]
Liver cirrhosis/cancer; hepatitis C virus [117]
Multiple sclerosis: a number of RNA and DNA viruses [118,119]
Paget’s bone disease: Measles and other paramyxoviruses [11,120]
Persistent arthralgia: Chikungunya virus [121]
Post-polio syndrome: poliovirus [122]
Progressive rubella panencephalitis; Rubella [113]
Subacute sclerosis panencephalitis and measles inclusion
encephalitis: measles virus [123]
Olfactory dysfunction; parainfluenza virus type 3 [124]
Otosclerosis: measles virus [125,126]can occasionally transmit the virus, thereby being a
potential source of future outbreaks [14,15]. Whilst no
one would suggest that the ability of Ebola virus to
establish persistent infections has evolved in humans,
the fact that even small numbers of individuals can
become persistently infected may reflect its intrinsic
ability to establish persistence in its natural host.
One potential advantage of persistent infection for the
infected host may be the maturation of the antiviral
immune response and development of long-lasting pro-
tective immunity. For instance, persistence of measles
virus RNA and protein in lymphoid tissue for months
after the primary infection stimulates continued produc-
tion of plasmablasts producing MeV-specific antibody of
increasing avidity, T cells of evolving functionality and
the establishment of life-long immunity that charac-
terizes recovery from measles [16,17]. Thus, there may
be clear advantages both for the virus and host in evolving
towards the establishment of persistent infections, espe-
cially because virus:host interactions that result in persis-
tent infections are unlikely, in most cases, to lead to high
levels of mortality.
Disease consequences of persistence
Although most persistent RNA virus infections are prob-
ably inapparent, persistent infections can sometimes lead
to chronic disease or relapses of acute disease. Long-
recognized examples include hepatocellular carcinoma
and liver fibrosis as a late consequence of HCV infection
[18], and SSPE following measles virus infection. Indeed,
the CNS, as an immunologically privileged site (see
below), is an organ in which RNA viruses can often
establish persistent infections with disease consequences
[5,19]. Recent examples include reactivation of CNS
infection after apparent recovery from Ebola virus disease
[14,20]. Other chronic human diseases have also been
linked to persistent RNA virus infections, some contro-
versially, including Paget’s bone disease, multiple sclero-
sis, otosclerosis, post-polio syndrome and other late
neurodegenerative diseases, chronic fatigue syndrome,
certain autoimmune diseases and exacerbation of chronic
obstructive pulmonary disease (Table 2).
The mechanisms by which persistent RNA virus infec-
tions induce chronic disease is poorly understood, but it
has been suggested that chronic stimulation of inflamma-
tory responses may be an important driving factor (see M.
K. McCarthy and T. E. Morrison, Persistent RNA virus
infections: do PAMPs drive chronic disease, in this issue
of Current Opinions in Virology).
Mechanisms of persistence
To establish persistent infections viruses must (i) avoid
elimination by the host’s immune response, and (ii) avoid
killing all infected cells whilst maintaining their genomes
within some infected cells. This may entail low level viruswww.sciencedirect.com replication within cells that themselves remain persis-
tently infected (e.g. BDV), infections in which the virus
slowly spreads from cell to cell, but during which the
infected cells may die (e.g. rabies virus), or infections in
which the virus passively hides without apparent replica-
tion (e.g. BTV in erythrocytes [21–23]). Both viral and host
factors will influence the type of persistent infection
established. For viruses that clearly need to establish
persistent infections to survive in nature the molecular
basis by which they do so must be an evolved process.
However, this is unlikely to be the case for viruses where
the establishment of persistence has no obvious selective
advantage for the virus, unless the general way the virus
replicates reflects the need of an ancestral virus to estab-
lish persistent infections, or the virus establishes advan-
tageous persistent infections in a different host.
Repression of virus transcription and replication
If a cell continues to synthesize high levels of viral
proteins, the cell will probably die either as a direct
consequence of virus replication or be eliminated by
innate and adaptive immune responses. Therefore, to
establish persistent infections virus replication probably
needs to be repressed in at least some infected cells.
Long-lived cells such as cardiac myocytes and brain and
spinal cord neurons may be particularly likely to restrict
virus replication and avoid immune-mediated elimination
(see below). However, RNA viruses can establish persis-
tent infections in a variety of tissues, not all of which are
immune privileged sites. How repression of virus repli-
cation is achieved in these cells, even for a well-studied
virus such as HCV, is usually not clear. HCV appears to
have evolved mechanisms to hijack cellular factors, such
as microRNAs that bind its genome to protect it from
degradation by the 50–30 exoribonuclease Xrn1 [24],
inhibit its detection by sensors of the innate immune
response and to regulate virus transcription, replication
and genomic RNA abundance [25]. BDV, linked toCurrent Opinion in Virology 2017, 23:35–42
38 Viral pathogenesisneurobehavioral disorders, is the only member of the
order Mononegavirales that replicates in the nucleus
and non-cytolytically infects animals to establish persis-
tence [26]. To maintain persistence, BDV tethers its
genome to host cell chromosomes, so that both daughter
cells remain infected when the cell divides [27]. BDV also
blocks apoptosis, and thus promotes persistence by pre-
venting cell death, through the action of its accessory
protein X [28], which may influence the establishment
and reactivation of BDV through its regulatory function
on virus polymerase activity [29]. Furthermore, 50-termi-
nal trimming, a mechanism that leads to the loss of
terminal nucleotides from the BDV genome, may atten-
uate virus replication and transcription (thereby also
helping to facilitate virus persistence), and prevent the
genome from activating innate immune responses, which
also strongly influence the outcome of virus infections
(see below) [30]. Similar modifications (deletions and
insertions) at the 50 and/or 30 ends of the genomes of
other RNA viruses, including LCMV, hantaviruses and
coxsackieviruses [31–33], may also play similar roles in
influencing their ability to establish persistent infections.
Certain insect and plant viruses also appear to have
evolved mechanisms, dependent upon the insect siRNA
defense system, to dampen down their replication
thereby facilitating virus persistence. Here, viral dsRNA
produced during virus replication is recognized by Dicer-
2 (DCR2), a central component of the siRNA pathway,
that processes the RNA to produce virus-derived siRNAs.
These are subsequently recognized by the RNA-induced
silencing complex (RISC) resulting in the specific cleav-
age of viral mRNA, thereby inhibiting lethal, acute infec-
tions and permitting virus persistence in the insect vector
[34,35]. The siRNA defense system may also suppress the
replication of mammalian arboviruses in their insect
vectors to levels that favour the establishment of persis-
tence and the survival of the vector [36]. However, it is
not known whether other RNA viruses, such as certain
paramyxoviruses, that can establish persistent infections
have also evolved specific mechanisms to down regulate
virus transcription and replication under certain condi-
tions. Nevertheless, it is interesting to speculate that the
reason some viruses can establish persistence in their
natural hosts but cause serious disease in other species
(e.g. hantaviruses [37,38], or possibly even Ebola virus), is
because the mechanisms they have evolved to dampen
replication in their natural hosts do not function in other
species.
It is unlikely that highly cytocidal viruses will be able to
establish persistent infections unless either some infected
cells are restrictive or semi-permissive for virus replica-
tion, or virus variants, including temperature sensitive
mutants [39], with reduced cytopathogenicity are
selected during the establishment of persistent infec-
tions. Such an outcome is much more likely for RNA
viruses than DNA viruses given the high mutation rate ofCurrent Opinion in Virology 2017, 23:35–42 RNA viruses and their quasispecies nature [40–43]. Simi-
larly, the presence and amplification of defective inter-
fering particles may also dampen virus replication and
thus influence the establishment of persistence [44–46]. A
rare way to establish RNA virus persistence, that is
unlikely to be of evolutionary benefit to the virus, is
the production of a cDNA copy of the viral RNA by
endogenous reverse transcriptase, as has occurred for
BDV and been proposed for measles virus and LCMV
[47–50].
One general way for viruses to restrict replication is
through limited activation of the interferon (IFN)
response. IFNs are cellular factors produced by infected
cells that interact with receptors on infected and unin-
fected cells to induce expression of antiviral proteins that
restrict virus replication. This is an extremely powerful
antiviral response that has co-evolved between virus and
host for millions of years and is a programmed response
that plays an essential role in controlling many virus
infections. Regulation of this innate response plays a role
in persistent hepatitis A infection of hepatocytes [51] and
arbovirus infection of mature neurons [52]. There is also
evidence that, for some viruses, variants that induce IFN,
or are relatively sensitive to IFN, may be better able than
the wild type viruses to establish persistent infections
[53,54].
Interaction with the immune system
A major host factor that profoundly influences the estab-
lishment of persistent infections is the competence of the
immune response and patients with immunodeficiencies
in innate, adaptive, or combined immune responses are
susceptible to development of persistent and progressive
infections with attenuated as well as wild type RNA
viruses. As examples, in addition to progressive disease
in severely immunodeficient children [55], children with
defects in the IFN response cannot rapidly clear the
attenuated viruses included in the measles-mumps-
rubella (MMR) vaccine, despite having an apparently
normal adaptive immune response [56,57]. Polymor-
phisms in the IFN-lambda response have been reported
to influence the outcome of HCV and its ability to
establish persistent infections [58]. Individuals with an
inability to make immunoglobulins (agammaglobulin-
emia) can become persistently infected with a variety
of RNA viruses, including echoviruses, enteroviruses,
rhinoviruses and parainfluenza viruses [11,59–61]. Fur-
thermore, immunodeficient individuals persistently
infected with poliovirus are a challenge for the WHO’s
vaccination campaign to eradicate poliomyelitis [62].
Indeed, given our advances in how to treat autoimmune
disease with immunosuppressive drugs and the survival
of patients with immunodeficient disorders, such individ-
uals, if they become persistently infected, may become
significant reservoirs for some infectious diseases and
nosocomial infections.www.sciencedirect.com
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individuals, viruses must avoid elimination by a fully
functional immune system, including innate and adaptive
responses. With regards innate responses, these include
avoidance of elimination by apoptosis [63] and the IFN
response. Indeed, to survive in nature all viruses must at
least partially circumvent the IFN response and to do so
they often hide, or modify their genomes, such that they
do not activate the IFN system, and/or produce proteins
that act as IFN antagonists [64]. The mechanisms by
which these IFN antagonists work potentially have a
strong influence on the ability of viruses to establish
persistent infections. Some lytic viruses (e.g. alpha-
viruses in vertebrate  hosts) block the IFN response
by inhibiting cellular transcription or protein synthesis,
which inevitably leads to cell death. Therefore, for
reasons discussed above, it is likely that non-cytolytic
variants will evolve during the establishment of persis-
tent infections. Other RNA viruses by nature are less
lytic, and produce IFN antagonists that allow cell sur-
vival and promote the establishment of virus persis-
tence. Indeed, the mechanisms of action of such viral
IFN antagonists may have specifically evolved to facili-
tate persistence.
To establish persistence viruses must also avoid elimina-
tion by antibody and T-cell responses, and this may
necessitate the down-regulation of virus protein synthesis
and replication (see above). Viruses may also establish
persistent infection in immunologically privileged sites
such as the brain or testis [5,65,66] and, although the brain
is likely to be a dead-end organ for the most viruses,
testicular infections can facilitate transmission [66–69].
The likelihood of persistence can also be influenced by
the promptness of the virus-specific antibody response
and relative timing of the appearance of populations of
effector and regulatory T cells. Viruses may be more
likely to persist if the effector response is suppressed
prior to clearance or if infection occurs at a very young age
and immunologic dysfunction/tolerance is established (e.
g. bovine viral diarrhoea virus infection in cattle, congeni-
tal rubella in humans, LCMV in mice) [70–72]. Viruses
can also suppress development of the adaptive antiviral
immune response and promote persistence by replicating
in cells and tissues of the immune system [73,74]. For
instance, bluetongue virus, an arthropod-borne reovirus,
infects and destroys follicular dendritic cells in germinal
centres of lymph nodes and prevents prompt develop-
ment of antibody capable of clearing infection [75].
Conversely it has also been suggested that an inappropri-
ate antibody response may facilitate persistence, as has
been suggested for MeV and Junin virus infections
[76,77]. How this may work is an open question, but
antibody-induced antigenic modulation can reduce the
level of measles viral glycoproteins on the surface of
persistently infected cells below that required for lysis
by antibody-dependent cellular cytotoxicity (ADCC), awww.sciencedirect.com mechanism by which specific immune cells, including
natural killer cells and macrophages, target virus-infected
cells [78]. Furthermore, antibodies against the measles
virus haemagglutinin can also reduce the expression of
viral proteins within cells, thereby potentially preventing
cell death and reducing the likelihood of the cells being
killed by the immune response [79,80].
To conclude, despite the fact that persistent RNA virus
infections can have important consequences both for the
virus and host, much has still to be learned about ‘Within
host persistent RNA virus’ infections. With the advent of
new technologies, such as next generation sequencing,
the tools are now available to better study persistent
infections both in vivo and in vitro. Such studies may
be used to investigate possible associations of persistent
virus infections with chronic human diseases. A better
understanding of the incidence and nature of persistent
RNA virus infections may also promote development of
better methods for surveillance and control; for example,
it may be possible to design improved vaccines using
viruses that establish persistent infections as vectors to
induce long lasting immunity.
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